![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
2MB |
Preview |
PDF (Supplemental Data)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
437kB |
| Item Type: | Article |
|---|---|
| Title: | Safety and efficacy of glofitamab for relapsed/refractory large B-cell lymphoma in a multinational real-world study |
| Creators Name: | Shumilov, E., Wurm-Kuczera, R., Kerkhoff, A., Wang, M., Melchardt, T., Holtick, U., Bacher, U., Staber, P.B., Mazzeo, P., Leng, C., Böckle, D., Hölscher, A.S., Kauer, J., Rotter, N., Vucinic, V., Rudzki, J.D., Nachbaur, D., Bücklein, V.L., Schnetzke, U., Krämer, I., Wille, K., Hasse, A., von Tresckow, B., Hänel, M., Koenecke, C., Velazquez, G.F., Viardot, A., Schmid, C., Thurner, L., Wolf, D., Subklewe, M., Dreyling, M., Dreger, P., Dietrich, S., Keller, U., Jäger, U., Greil, R., Pabst, T., Lenz, G. and Chapuy, B. |
| Abstract: | Glofitamab, a bispecific antibody targeting CD20 and CD3, is approved for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) after at least 2 prior treatment lines, but real-world data are scarce. In this retrospective, multicenter, multinational study, we evaluated the outcomes of 70 patients with r/r DLBCL treated with glofitamab as part of the compassionate use patient program in Germany, Austria, and Switzerland. The median number of prior treatment lines was 4, with 71% of patients refractory to their last treatment. Cytokine release syndrome was observed in 40% of patients (grade 3-4 in 2%), immune effector cell–associated neurotoxicity syndrome in 10% (grade 3 in 1%), and infections in 31% (grade 5 in 3%). The overall response rate was 46%, with 27% achieving complete responses (CR) and 19% partial responses. The median progression-free survival (PFS) was 3.6 months, whereas the median overall survival was 5.7 months. Notably, 13 patients (19%) were in CR 6 months after initiating glofitamab and exhibited durable responses. Elevated lactate dehydrogenase is the most robust predictor of inferior outcome. Patients pretreated with bendamustine within 6 months prior to glofitamab initiation exhibited significantly reduced PFS, suggesting that bendamustine may impair T-cell fitness and hence glofitamab efficacy. In summary, glofitamab demonstrates promising efficacy and a manageable safety profile in heavily pretreated patients with r/r DLBCL in a real-world scenario and the optimal sequence of treatments should use T-cell–depleting agents before glofitamab with caution. |
| Keywords: | Bispecific Antibodies, Diffuse Large B-Cell Lymphoma, Immunological Antineoplastic Agents, Recurrence, Retrospective Studies, Treatment Outcome |
| Source: | Blood Advances |
| ISSN: | 2473-9529 |
| Publisher: | American Society of Hematology |
| Volume: | 9 |
| Number: | 15 |
| Page Range: | 3865-3877 |
| Date: | 12 August 2025 |
| Official Publication: | https://doi.org/10.1182/bloodadvances.2024014903 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
